Literature DB >> 1606341

Generalized seizures secondary to high-dose busulfan therapy.

C P Murphy1, E A Harden, J M Thompson.   

Abstract

Two patients without prior histories of neurologic disorders experienced generalized seizures while receiving high-dose busulfan (total dose 16 mg/kg) as part of a preparative regimen for allogeneic bone marrow transplantation. A review of the literature revealed 14 similar occurrences. Maintenance of therapeutic blood concentrations of phenytoin in subsequent patients at our institution has resulted in no further patients experiencing generalized seizures. Prophylactic anticonvulsant therapy should be considered in patients receiving high doses of busulfan.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1606341     DOI: 10.1177/106002809202600107

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  5 in total

1.  Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning.

Authors:  Jeannine S McCune; Tao Wang; Khalid Bo-Subait; Mahmoud Aljurf; Amer Beitinjaneh; Joseph Bubalo; Jean-Yves Cahn; Jan Cerny; Saurabh Chhabra; Aaron Cumpston; L Lee Dupuis; Hillard M Lazarus; David I Marks; Richard T Maziarz; Maxim Norkin; Tim Prestidge; Shin Mineishi; Maxwell M Krem; Marcelo Pasquini; Paul J Martin
Journal:  Biol Blood Marrow Transplant       Date:  2019-03-11       Impact factor: 5.742

2.  Minimal incidence of neurotoxicity without prophylaxis during busulfan-based conditioning regimen in patients undergoing stem cell transplantation.

Authors:  Eucario Leon-Rodriguez; Monica M Rivera-Franco
Journal:  Int J Hematol       Date:  2016-10-08       Impact factor: 2.490

3.  Delayed, transient encephalopathy after marrow transplantation: case reports and MRI findings in four patients.

Authors:  H I Tahsildar; B F Remler; R J Creger; B W Cooper; S M Snodgrass; R W Tarr; H M Lazarus
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

4.  Phenytoin as seizure prophylaxis in hematopoietic stem cell transplantation with busulfan conditioning.

Authors:  R S Germeraad; A M P Demandt; R P W Rouhl
Journal:  Front Neurol       Date:  2022-08-22       Impact factor: 4.086

5.  The Case for Laboratory Developed Procedures: Quality and Positive Impact on Patient Care.

Authors:  Karen L Kaul; Linda M Sabatini; Gregory J Tsongalis; Angela M Caliendo; Randall J Olsen; Edward R Ashwood; Sherri Bale; Robert Benirschke; Dean Carlow; Birgit H Funke; Wayne W Grody; Randall T Hayden; Madhuri Hegde; Elaine Lyon; Kazunori Murata; Melissa Pessin; Richard D Press; Richard B Thomson
Journal:  Acad Pathol       Date:  2017-07-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.